Back to News
Market Impact: 0.2
Cantor Fitzgerald Initiates Coverage of Ensysce Biosciences at Overweight
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Cantor Fitzgerald initiated coverage of Ensysce Biosciences on October 20, 2026, with an Overweight recommendation. Ensysce shares closed at $0.51 that day; the article provides no prior-session closing price or reported market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
ENSC0.55
More News
- Why is Contemporary Amperex Technology stock sliding today?
- Capital One's strong quarter and progressing Discover integration are rewarded on Wall Street
- SpaceX Earnings Blow Past Wall Street Estimates
- A top medical technology stock is trading at a big discount. Here's why I'm buying
- Obsessed with CoreWeave and the AI trade? You're missing out on some great stocks
- UnitedHealthcare and Humana are ending Medicare Advantage plans for nearly 1 million people
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AllMind Discusses Ontario's AI Economy with Minister Stephen Crawford and Supply Ontario CEO James Wallace
- AI Research Tools for SEDAR+, UK and ASX Filings